home / stock / bngo / bngo news


BNGO News and Press, Bionano Genomics Inc. From 02/14/23

Stock Information

Company Name: Bionano Genomics Inc.
Stock Symbol: BNGO
Market: NASDAQ
Website: bionanogenomics.com

Menu

BNGO BNGO Quote BNGO Short BNGO News BNGO Articles BNGO Message Board
Get BNGO Alerts

News, Short Squeeze, Breakout and More Instantly...

BNGO - Bionano Shares Overview of AGBT Pre-Conference Workshop Program Along with Details of Company's Innovative Research Grant Opportunity

Bionano leaders presented on the ability of optical genome mapping (OGM) to potentially replace traditional cytogenetic methods for structural variant (SV) detection and shared details of the company’s new product advancements Bionano and NVIDIA previewed their collaborative de...

BNGO - Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week

After a blistering start to the year, small-cap biotech stocks made a U-turn in the second week of February. Speaking to this point, shares of the optical genome mapping company Bionano Genomics (NASDAQ: BNGO) , the next-generation DNA sequencing company Pacific Biosciences of Californi...

BNGO - Bionano Strategy Day Highlighted the Company's Strategic Initiatives and Growth Plans as well as OGM's Competitive Value for Cell Bioprocessing, and Cancer and Genetic Disease Research

Bionano’s chief executive officer, chief financial officer, chief medical officer, chief operating officer and vice president of clinical and scientific affairs delivered an in-depth review of the company’s strategy, growth drivers, and financial objectives, as well as key initi...

BNGO - Bionano's Symposium 2023 Featured Record Numbers of Presentations Demonstrating Applications of OGM Across Cell Bioprocessing and Constitutional Genetic Disease and Cancer Research

Over 3,000 registrants with attendees from 114 countries Average daily attendance of 750 in 2023 versus 565 in 2022 31 oral presentations delivered across four consecutive days 69 scientific posters featuring optical genome mapping (OGM) on view in the online exhibit hal...

BNGO - Bionano's Balance Sheet Challenges: History Repeating Itself

Summary BNGO reported preliminary Q4 results, showing acceptable core business performance. Aggressive expansion into capital-intensive markets could put significant pressure on BNGO's balance sheet. Recently-introduced LDTs will likely have a limited impact on revenue growth. ...

BNGO - Bionano Laboratories Expands its Clinical Testing Menu with Launch of its First OGM-Based Laboratory Developed Test (LDT) for Hematological Malignancies

SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the launch of OGM-Dx™ HemeOne™, a laboratory developed test (LDT) based on optical genome mapping (OGM) analysis of blood or bone marrow samples to detect structural variants (SVs) of diagnostic and pr...

BNGO - Bionano Announces Launch of Next-Generation Versions of its Reagent Kits and Chip Consumable, Along with Updates to its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow

Bionano Prep SP-G2 (SP-G2) kit offers higher gDNA quality, improved ease-of-use and increased DNA throughput Bionano Prep Direct Label and Stain-G2 (DLS-G2) kit offers increased reagent stability and labeling efficiency resulting in significantly faster sample to results workflow ...

BNGO - Bionano Genomics Announces the Final Speaker Lineup for Symposium 2023 with 30 OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Research Applications

27 different customers representing North America and Europe 30 oral presentations across four consecutive days 34 scientific posters will be featured in a virtual exhibition hall Topics span the application of optical genome mapping (OGM) in genetic disease, cancer r...

BNGO - Bionano Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing

IRB-approved, multi-site, ongoing study evaluated 200 samples representing 123 unique prenatal cases across 9 sites for interim measures of key endpoints: Results of OGM analysis were comparable, in a single assay, to the results of two separate standard of care (SOC) tests needed to re...

BNGO - Inotiv: High Expenses Likely To Impair Long-Term Profitability

Summary Inotiv's recently acquired companies cause its revenue to spike tremendously. However, the company's expenses are just as great, and not all of the largest cost items are one-time costs, meaning the company could remain unprofitable for a long time. Specifically, the Goodwil...

Previous 10 Next 10